Immutep Limited (ASX: IMM; NASDAQ: IMMP) announced today, 20 October 2025, that its investigator‑initiated EFTISARC‑NEO Phase II trial met its primary endpoint. The data were presented in a proffered paper oral presentation at the 2025 European Society of Medical Oncology (ESMO) Congress in Berlin, Germany, and evaluated eftilagimod alfa (efti) in combination with radiotherapy plus KEYTRUDA® (pembrolizumab) in the neoadjuvant setting for resectable soft tissue sarcoma (STS).
In the evaluable population of 38 patients, the combination achieved a median tumor hyalinization/fibrosis of 51.5% (p<0.001), more than three times the prespecified 35% target and exceeding the 15% rate seen with standard‑of‑care radiotherapy alone. The safety profile was favorable, with only one grade ≥ 3 toxicity attributable to immunotherapy. The results confirm the early surrogate endpoint of tumor fibrosis, which is correlated with improved overall survival and recurrence‑free survival in STS patients.
These findings represent a significant operational milestone for Immutep, reinforcing the therapeutic potential of its LAG‑3 platform in a disease with high unmet need. The data support the company’s strategy to advance eftilagimod alfa as a novel treatment option for soft tissue sarcoma and underscore the broader impact of its immunotherapy approach in oncology.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.